Dr. Peter Martin Discusses RBAC500: A Combination of Cytarabine with Rituximab and Bendamustine for Elderly Patients with Mantle Cell Lymphoma

healio

In an interview recorded during the 2016 American Society of Hematology Annual Meeting, Dr. Peter Martin discussed  results from a phase 2 trial where researchers from the Fondazione Italiana Linfomi found that the addition of intermediate-dose of cytarabine to the first line treatment of rituximab and bendamustine led to a 91% response rate in elderly people with mantle cell lymphoma. This chemotherapy combination is known as RBAC500.

Dr. John Leonard Discusses Results from the GALLIUM Trial for Patients with Previously Untreated Follicular Lymphoma

jl

Click on the graphic above to watch this interview from the 2016 annual meeting of the American Society of Hematology, Lymphoma Program Director, Dr. John Leonard discusses results from the recently completed GALLIUM trial. In this trial researchers compared the safety and efficacy of either rituximab or obinutuzumab with chemotherapy followed by maintenance with the same agent as first-line therapy for patients with previously untreated follicular lymphoma.

Dr. Peter Martin on Promise of Ibrutinib + Palbociclib for Previously Treated Mantle Cell Lymphoma

pm-pic

In an interview with MDLinx during the 2016 American Society of Hematology Annual Meeting, Dr. Peter Martin discusses results from a phase I clinical trial designed to evaluate the safety and activity of ibrutinib plus palbociclib in people with previously treated MCL.